Puretech initiates late-stage clinical study of wholly-owned candidate lyt-100 (deupirfenidone) in ipf and advances lyt-200 (anti-galectin-9 mab)

Boston--(business wire)--puretech initiates late-stage clinical study of wholly-owned candidate lyt-100 (deupirfenidone) in ipf and advances lyt-200 (anti-galectin-9 mab)
PRTC Ratings Summary
PRTC Quant Ranking